Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

GH secretagogues under development at Merck

Dec. 23, 1997

Lilly research leads to the discovery of new antiobesity compounds

Dec. 23, 1997

Isolation, structural elucidation and preliminary biological evaluation of new XOD inhibitor

Dec. 22, 1997

Flt3 ligand stimulates production of fully functional dendritic cells

Dec. 22, 1997

Hemolink enters phase II trials for second indication

Dec. 19, 1997

Nutropin AQ also wins FDA approval

Dec. 19, 1997

Positive phase IIa results reported for Cortecs' oral insulin

Dec. 19, 1997

CholestaGel enters phase III testing

Dec. 19, 1997

RSD-992: a novel 5-HT antagonist with erectogenic activity

Dec. 19, 1997

FDA approves Nutropin for GH deficiency in adults

Dec. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...